Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global leader in the pharmaceutical, medical device, and over-the-counter product industries, primarily focusing on the therapeutic areas of eye health, gastroenterology, and dermatology. The company is dedicated to advancing global health through innovation and efficient healthcare solutions.
With approximately 22,000 employees worldwide, Bausch Health operates in around 100 countries. The company's core business is organized into five segments: Salix Pharmaceuticals, International, Solta Medical, Diversified Products, and Bausch + Lomb, with the Bausch + Lomb segment generating the highest revenue. Bausch Health consistently delivers on its commitments to quality health care outcomes and customer focus.
Recent achievements include significant progress in the development of Amiselimod, a promising new treatment for ulcerative colitis, and the expansion of public drug plan listings for UCERIS® (budesonide) aerosol foam in multiple Canadian provinces. Additionally, Bausch Health has launched an awareness campaign for XIFAXAN®, an FDA-approved medication for reducing the risk of overt hepatic encephalopathy recurrence.
Financially, Bausch Health reported strong performance in the first quarter of 2024, with revenues of $2.15 billion, marking a 11% increase compared to the prior year. The company continues to strengthen its balance sheet while advancing its R&D pipeline and executing commercial strategies for global growth.
Bausch Health remains focused on protecting its intellectual property, as evidenced by recent litigation efforts to defend the XIFAXAN® franchise. The company is also committed to fostering partnerships and collaborations to enhance its product offerings and reach.
For more information, visit www.bauschhealth.com.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that it will present seven research posters for its products XIFAXAN®, TRULANCE®, and PLENVU® at Digestive Disease Week 2022 from May 21-24, 2022, in San Diego, California. The posters highlight significant findings, such as the efficacy of XIFAXAN in managing hepatic encephalopathy and IBS-D, TRULANCE's rapid response in treating IBS-C, and PLENVU’s high-quality bowel cleansing for colonoscopy preparations. The research results will be publicly accessible on DDW's ePoster website starting May 21, 2022.
KBRA has published its First-Quarter 2022 U.S. Bank Compendium, offering insights into the banking sector's performance. The report highlights the impact of inflation on vehicle prices and auto loan exposures within the KBRA-rated banks. It includes summaries of 1Q22 results for publicly traded U.S. banks, focusing on key performance metrics and credit ratios. Additionally, the Compendium features the top 10 low-cost deposit franchises and a detailed supplement of 171 debt issues rated by KBRA.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced its participation in investor conferences, including the Goldman Sachs Leveraged Finance and Credit Conference on May 12, 2022, and the Barclays High Yield Bond & Syndicated Loan Conference on May 24, 2022. Key executives such as Tom Vadaketh and Christina Cheng will represent the company. Live webcasts of these events will be accessible on the Investor Relations page of their website. Bausch Health focuses on enhancing global health through a diverse range of pharmaceutical products.
Bausch + Lomb Corporation and Bausch Health Companies announced the closing of Bausch + Lomb's IPO, selling 35 million shares at $18.00 each, generating $630 million. Bausch Health retains approximately 90% of Bausch + Lomb's shares. The IPO proceeds and new loans will be used to repay existing debts, including Bausch Health’s 6.125% Notes due 2025. Bausch Health also canceled the redemption of its 9.000% Senior Notes due 2025. The IPO began trading under the ticker symbol BLCO on May 6, 2022.
Bausch Health Companies Inc. (NYSE/TSX: BHC) reported first-quarter 2022 revenues of $1.918 billion, a 5% decrease from $2.027 billion in Q1 2021. Despite challenges, organic growth remained stable year-over-year. The company recorded a GAAP net loss of $69 million, an improvement from a $610 million loss in the same quarter last year. Adjusted EBITDA fell to $732 million, down from $852 million. Bausch + Lomb has begun trading under the 'BLCO' ticker following its IPO, which is expected to generate $630 million to reduce long-term debt. The full-year revenue guidance is set between $8.25 billion and $8.4 billion.
Bausch Health Companies Inc. (NYSE/TSX: BHC) has appointed Thomas J. Appio as CEO and announced its leadership team and Board of Directors. Following the IPO of Bausch + Lomb, Joseph C. Papa will transition to chairman and CEO of Bausch + Lomb. The new executive team comprises experienced leaders, including Thomas Vadaketh as CFO and Seana Carson as General Counsel. Richard Mulligan, Ph.D., was appointed to the Board. The full separation of Bausch + Lomb is expected to finalize on May 10, 2022, with shares trading under the symbol 'BHC'.
Bausch + Lomb Corporation, a subsidiary of Bausch Health (NYSE/TSX: BHC), has announced the pricing of its initial public offering (IPO) of 35 million common shares at $18.00 each. Bausch + Lomb will not receive the proceeds from this offering, as it is being conducted by the Selling Shareholder. The shares are set to trade on the NYSE and TSX under the ticker symbol 'BLCO' starting May 6, 2022. Following the IPO, Bausch Health will retain around 90% of Bausch + Lomb's shares, decreasing to 88.5% if the underwriters' over-allotment option is fully exercised.
Bausch Health and Novaliq announced that their investigational treatment NOV03 successfully met primary endpoints in two pivotal Phase 3 trials for treating dry eye disease (DED) associated with Meibomian gland dysfunction (MGD). The latest trial results demonstrated significant improvements in total corneal fluorescein staining and eye dryness scores at day 57. With potential FDA submission in Q2 2022, NOV03 could become the first pharmaceutical therapy available in the U.S. targeting this common ocular condition affecting approximately 18 million Americans.
Bausch Health Companies (NYSE/TSX: BHC) will announce its first-quarter financial results on May 10, 2022. A conference call and live webcast will be held at 8:00 a.m. ET to discuss these results and provide a business update. Investors can access materials through the Investor Relations section of the Bausch Health website before the call.
Bausch + Lomb Corporation, a subsidiary of Bausch Health Companies (NYSE/TSX: BHC), has announced its initial public offering (IPO), offering 35 million common shares with an expected price range of $21 to $24 per share. A 30-day option for underwriters to purchase an additional 5.25 million shares is also planned. Post-IPO, Bausch Health will hold approximately 90% of Bausch + Lomb's shares. The IPO aims for listing on the NYSE and TSX under the ticker symbol 'BLCO'. Bausch + Lomb will not receive any IPO proceeds.
FAQ
What is the current stock price of Bausch Health Companies (BHC)?
What is the market cap of Bausch Health Companies (BHC)?
What are the primary areas of focus for Bausch Health?
How many employees does Bausch Health have?
In how many countries does Bausch Health operate?
What is Bausch Health's largest revenue-generating segment?
What recent product development has Bausch Health achieved?
What financial performance did Bausch Health report for Q1 2024?
How is Bausch Health protecting its intellectual property?
Where can I find more information about Bausch Health?
What recent public drug plan listings has Bausch Health achieved in Canada?
Who is the brand ambassador for the XIFAXAN® awareness campaign?
